CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02903511
NCT02903511Phase 2Completed
CompareCT.gov

Feasibility Study of Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease.

University of Colorado, Denver·interventional·Posted Sep 16, 2016·Updated Sep 5, 2021

In Brief

A Phase 2 clinical trial evaluating Metformin and Placebo for Polycystic Kidney, Autosomal Dominant. Completed, enrolled 56 participants across 1 site.

Detailed Summary

This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who are not diabetic and who have slightly decreased kidney function. The study will also evaluate the effects of metformin on kidney growth and kidney function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Kidney, Autosomal Dominant
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 16, 2016
Enrollment StartNov 1, 2016
Primary CompletionAug 17, 2020
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 9.8 years ago

Interventions

Metformindrug

Monitoring of safety and tolerability

Placebodrug

Monitoring of safety and tolerability